Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2021
>
A new collaboration deal with Eli Lilly could be worth up to $1.3 billion
A new collaboration deal with Eli Lilly could be worth up to $1.3 billion
Read also
AstraZeneca and Daiichi’s Datroway
AstraZeneca and Daiichi’s Datroway trumps chemo in first-line breast cancer
McMaster University and MIT
McMaster University and MIT discover new antibiotic for IBD
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
IGC Pharma's Preclinical Data for IGC-1C
IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
